Total Payments
$11,461
2024 Payments
$2,356
Companies
37
Transactions
542
Medicare Patients
12,880
Medicare Billing
$815,767
Payment Breakdown by Category
Food & Beverage$11,262 (98.3%)
Education$197.09 (1.7%)
Other$2.37 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,262 | 534 | 98.3% |
| Education | $197.09 | 6 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.37 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $1,431 | 58 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,230 | 72 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,018 | 59 | $0 (2024) |
| Amgen Inc. | $1,012 | 42 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $652.43 | 17 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $574.63 | 36 | $0 (2024) |
| United Therapeutics Corporation | $512.63 | 10 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $505.14 | 30 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $487.19 | 22 | $0 (2024) |
| PFIZER INC. | $470.23 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,356 | 89 | Actelion Pharmaceuticals US, Inc. ($438.97) |
| 2023 | $1,580 | 77 | Novartis Pharmaceuticals Corporation ($314.06) |
| 2022 | $1,096 | 61 | Novartis Pharmaceuticals Corporation ($251.32) |
| 2021 | $626.13 | 21 | AstraZeneca Pharmaceuticals LP ($184.94) |
| 2020 | $654.54 | 22 | Amarin Pharma Inc. ($137.93) |
| 2019 | $1,740 | 90 | Actelion Pharmaceuticals US, Inc. ($295.29) |
| 2018 | $1,472 | 85 | Boehringer Ingelheim Pharmaceuticals, Inc. ($187.30) |
| 2017 | $1,937 | 97 | United Therapeutics Corporation ($360.42) |
All Payment Transactions
542 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.17 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: DIABETES | ||||||
| 11/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Cardiology | ||||||
| 11/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Obesity | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: Cardiovascular | ||||||
| 11/09/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $25.71 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/02/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $15.74 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.55 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/29/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/24/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: Cardiology | ||||||
| 09/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Cardio-pulmonary | ||||||
| 09/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Obesity | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $29.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: DIABETES | ||||||
| 09/05/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/03/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $20.38 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,600 | 2,962 | $794,737 | $168,824 |
| 2022 | 23 | 2,811 | 3,183 | $753,776 | $183,757 |
| 2021 | 22 | 3,785 | 4,266 | $918,591 | $246,440 |
| 2020 | 20 | 3,684 | 4,076 | $856,372 | $216,747 |
Total Patients
12,880
Total Services
14,487
Medicare Billing
$815,767
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 791 | 1,060 | $392,200 | $88,083 | 22.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 415 | 423 | $106,596 | $20,796 | 19.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 74 | 130 | $46,150 | $11,775 | 25.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 156 | 156 | $42,276 | $7,890 | 18.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 76 | 78 | $36,504 | $7,791 | 21.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 43 | $29,713 | $5,475 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 41 | $20,336 | $5,192 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $24,123 | $4,705 | 19.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 263 | 267 | $19,421 | $2,675 | 13.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 41 | $10,209 | $2,521 | 24.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 146 | 146 | $11,242 | $2,058 | 18.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 29 | $7,337 | $1,678 | 22.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 159 | 159 | $8,109 | $1,519 | 18.7% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 22 | 22 | $6,996 | $1,352 | 19.3% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 14 | 14 | $6,314 | $1,069 | 16.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 108 | 122 | $4,270 | $771.04 | 18.1% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 11 | 11 | $9,790 | $753.20 | 7.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 15 | 15 | $3,780 | $740.32 | 19.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 12 | $1,848 | $511.44 | 27.7% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 25 | 25 | $2,400 | $480.75 | 20.0% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 33 | 33 | $2,277 | $437.76 | 19.2% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 17 | 17 | $1,530 | $313.92 | 20.5% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 56 | 56 | $784.00 | $131.64 | 16.8% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 19 | 19 | $532.00 | $105.45 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 923 | 1,195 | $339,258 | $95,242 | 28.1% |
About Dr. Mac Bowman, MD
Dr. Mac Bowman, MD is a Cardiovascular Disease healthcare provider based in Augusta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972549046.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mac Bowman, MD has received a total of $11,461 in payments from pharmaceutical and medical device companies, with $2,356 received in 2024. These payments were reported across 542 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($11,262).
As a Medicare-enrolled provider, Bowman has provided services to 12,880 Medicare beneficiaries, totaling 14,487 services with total Medicare billing of $815,767. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Augusta, GA
- Active Since 06/20/2006
- Last Updated 02/28/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1972549046
Products in Payments
- UPTRAVI (Drug) $973.14
- ENTRESTO (Drug) $761.31
- Repatha (Biological) $741.32
- ELIQUIS (Drug) $643.20
- JARDIANCE (Drug) $559.91
- XARELTO (Drug) $531.29
- FARXIGA (Drug) $522.44
- ORENITRAM (Drug) $510.26
- LifeVest (Device) $487.19
- LEQVIO (Drug) $468.45
- PRADAXA (Drug) $458.13
- OPSUMIT (Drug) $325.03
- VERQUVO (Drug) $263.04
- Corlanor (Drug) $261.12
- Vascepa (Drug) $258.87
- Adempas (Drug) $233.66
- PRALUENT (Drug) $221.10
- Bidil (Drug) $182.67
- CAMZYOS (Drug) $180.34
- Wegovy (Drug) $139.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Augusta
Dr. Wayne Kaesemeyer, Md, MD
Cardiovascular Disease — Payments: $62,122
Cardiovascular Disease $62,122
Avirup Guha, M.b.b.s, M.B.B.S
Cardiovascular Disease — Payments: $45,106
Cardiovascular Disease $45,106
Daniel Sohinki, M.d, M.D
Cardiovascular Disease — Payments: $26,674
Cardiovascular Disease $26,674
Brian Annex, M.d, M.D
Cardiovascular Disease — Payments: $25,928
Cardiovascular Disease $25,928
Kimberly Atianzar, M.d, M.D
Cardiovascular Disease — Payments: $23,376
Cardiovascular Disease $23,376
Adam Berman, M.d, M.D
Cardiovascular Disease — Payments: $19,682
Cardiovascular Disease $19,682